Prednisone is the mainstay of sarcoidosis treatment. However, prednisone treatment optimisation is warranted, since prolonged high-dose prednisone therapy is associated with burdensome and harmful side-effects [1, 2]. Early prednisone dose tapering has the potential to reduce side-effects. Gaining insight in the early treatment response can help to determine when tapering could be initiated. To date, there are no prospective studies that look at early treatment response to prednisone in sarcoidosis by monitoring clinical symptoms and daily patient-administered lung function. Therefore, we initiated a multicentre, prospective and observational study with daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis (Dutch National Trial Register NTR4328; www.trialregister.nl/trialreg). The major treatment effect of prednisone on FVC is reached within 2 to 3 weeks in newly treated sarcoidosis patients http://ow.ly/3A3E30h5ZuT

中文翻译：

---

每日家庭肺活量测定法检测新治疗肺结节病的早期类固醇治疗效果

泼尼松是结节病治疗的中流砥柱。然而，有必要优化泼尼松治疗，因为长时间的大剂量泼尼松治疗会带来沉重和有害的副作用 [1, 2]。早期的泼尼松剂量逐渐减少有可能减少副作用。深入了解早期治疗反应有助于确定何时可以开始逐渐减量。迄今为止，还没有前瞻性研究通过监测临床症状和患者每日给药的肺功能来观察结节病患者对泼尼松的早期治疗反应。因此，我们启动了一项多中心、前瞻性和观察性研究，每天进行家庭肺活量测定，以检测新治疗的肺结节病的早期类固醇治疗效果（荷兰国家试验注册 NTR4328；www.trialregister.nl/trialreg）。